E2F3 transcription factor: A promising biomarker in lung cancer
E2F3 transcription factor: A promising biomarker in lung cancer
复制标题
DOI：
10.3233/cbm-160196
复制
发表时间：
2017-01-01
影响因子：
3.1
通讯作者：
Nada, Ola
中科院分区：
文献类型：
--
作者：
Al Ahmed, Hala Abdel;Nada, Ola
背景：许多旨在探讨肺癌发病机制的研究对肺癌的分子改变进行了广泛的研究。目的：本研究采用实时RT-PCR技术检测血液E2F3 mRNA，以评估其在肺癌早期诊断和监测中的临床意义。方法：本病例对照研究包括50例肺癌患者、20例肺部良性疾病患者和20例健康体检者。 控制。通过实时 RT-PCR 进行血液 E2F3 mRNA 的相对定量。结果：与良性肺部疾病患者或健康受试者相比，肺癌患者的血液 E2F3 mRNA 水平显着较高。与局限性肺癌患者相比，这种升高在转移性肺癌患者中更为显着。在截止值 ((2-Delta Delta CT))1.5 时，血液 E2F3 mRNA 能够区分恶性和良性肺部疾病，诊断灵敏度为 100%；当截止值((2-Delta Delta CT))5.3时，血液E2F3 mRNA可区分局部转移性肺癌，敏感性为93.6%。结论：血液E2F3 mRNA是肺癌的敏感诊断标志物。此外，它是一种有前途的预后标志物，能够有效地区分疾病的早期阶段和晚期阶段。
BACKGROUND: Many researches aiming to explore the pathogenesis of lung cancer have extensively studied the molecular alteration in such disease.OBJECTIVE: In the present study we measured the blood E2F3 mRNA using real-time RT-PCR technique in order to evaluate its clinical significance in early diagnosis and monitoring of lung cancer.METHODS: This case-control study included 50 lung cancer patients, 20 patients with benign lung diseases and 20 healthy controls. Relative quantification of blood E2F3 mRNA was done by real-time RT-PCR.RESULTS: Blood E2F3 mRNA levels were significantly higher in lung cancer patients when compared to either patients with benign lung diseases or healthy subjects. This elevation was significant in those with metastatic lung cancer as compared to those with localized lung cancer. At a cutoff((2-Delta Delta CT))1.5, blood E2F3 mRNA was able to distinguish malignant from benign lung conditions with a diagnostic sensitivity of 100%; while at a cutoff((2-Delta Delta CT))5.3, blood E2F3 mRNA discriminated localized from metastatic lung cancer with a sensitivity of 93.6%.CONCLUSIONS: Blood E2F3 mRNA is a sensitive diagnostic marker in lung cancer; moreover, it is a promising prognostic marker capable of efficiently discriminating early from late stages of the disease.